- Home
- WRN vs LXRX Comparison
WRN vs LXRX Comparison
Compare WRN & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.44
HOLD
Current Price
$1.63
Company Overview
Basic Information| Metric | WRN | LXRX |
|---|---|---|
| Founded | 2006 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 676.9M | 547.4M |
| IPO Year | 2006 | 2000 |
Fundamental Metrics
Financial Performance| Metric | WRN | LXRX |
|---|---|---|
| Price | $2.44 | $1.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $4.88 | $4.15 |
| AVG Volume (30 Days) | 1.6M | ★ 2.4M |
| Earning Date | 05-08-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $0.90 | $0.32 |
| 52 Week High | $4.26 | $1.83 |
Technical Indicators
Market Signals| Indicator | WRN | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 55.40 |
| Support Level | $2.43 | $1.08 |
| Resistance Level | $2.56 | $1.65 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 19.78 | 51.47 |
Price Performance
Historical Comparison WRN
LXRX
About WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.